RephImmune is a preclinical-stage biotech company incubated in Boston and incorporated in Taiwan. We are dedicated to revolutionizing solid tumor cell therapy through our groundbreaking technology, RACE (Reconstitute-Immunity Antigen-Cell Engager): a unique engine in engineered cell therapy. Unlike conventional cell therapies, RACE bypasses traditional signaling pathways, unlocking the full potential of immune cells. With unparalleled advantages evident in pre-clinical data, RACE stands out in transformative advancements. Join us in accelerating RACE breakthroughs to have a clinical impact on more cancer patients!